Plasma metabolite biomarkers for the detection of pancreatic cancer

Journal of Proteome Research

Volumn 14, Issue 2, 2015, Pages 1195-1202

  Xie, Guoxiang ^a,b   Lu, Lingeng ^c   Qiu, Yunping ^d   Ni, Quanxing ^e   Zhang, Wei ^f   Gao, Yu Tang ^f   Risch, Harvey A ^c   Yu, Herbert ^b   Jia, Wei ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c YALE UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

GC MS; LC MS; logistic regression; metabonomics; multivariate statistical analysis; OPLS DA; Pancreatic cancer; plasma; ROC

Indexed keywords

1,3,7 TRIMETHYLURIC ACID; 1,5 ANHYDRO GLUCITOL TALOPYRANOSE; 1,5 ANHYDROSORBITOL; 2 AMINOBUTYRIC ACID; 2 OXOGLUTARIC ACID; 2,4 DIAMINOBUTYRIC ACID; 3 AMINO 2 PIPERIDONE; ACEGLUTAMIDE; ADENINE; BETAINE; CHOLINE; COUMARIC ACID; CREATININE; GALACTITOL; GENTISIC ACID; GLUTAMIC ACID; GLYCOCHOLIC ACID; INDOLEACETIC ACID; INDOLEACRYLIC ACID; LYSOPC; METHYLGUANIDINE; MONOISOBUTYL PHTHALIC ACID; NICOTINIC ACID MONONUCLEOTIDE; PROLINE; PROPIONYLCARNITINE; TRYPTOPHAN; TUMOR MARKER; UNCLASSIFIED DRUG; UREA; URIC ACID; VALINE; BIOLOGICAL MARKER;

AGED; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLITE; METABOLOMICS; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; TIME OF FLIGHT MASS SPECTROMETRY; ADULT; BLOOD; MASS SPECTROMETRY; MIDDLE AGED; PANCREATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 84922627331     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr501135f     Document Type: Article

References (47)

1. Gong, Z.; Holly, E. A.; Bracci, P. M. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999 Am. J. Epidemiol. 2011, 174, 1373-81
2. Cancer Facts & Figures; American Cancer Society, Inc: Atlanta, GA, 2014.
3. Brand, R. The diagnosis of pancreatic cancer Cancer J. 2001, 7, 287-97
4. Hidalgo, M. Pancreatic cancer N. Engl. J. Med. 2010, 362, 1605-17
5. What you need to know about cancer of the pancreas; National Cancer Institute, U.S. Department of Health and Human Services: Bethesda, MD, 2001.
6. Brenner, D. J.; Hall, E. J. Computed tomography-an increasing source of radiation exposure N. Engl. J. Med. 2007, 357, 2277-84
7. Brand, R. E.; Matamoros, A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas Dig. Dis. 1998, 16, 242-52
8. Rosty, C.; Goggins, M. Early detection of pancreatic carcinoma Hematol. Oncol. Clin. North Am. 2002, 16, 37-52
9. Brand, R. E.; Nolen, B. M.; Zeh, H. J.; Allen, P. J.; Eloubeidi, M. A.; Goldberg, M.; Elton, E.; Arnoletti, J. P.; Christein, J. D.; Vickers, S. M.; Langmead, C. J.; Landsittel, D. P.; Whitcomb, D. C.; Grizzle, W. E.; Lokshin, A. E. Serum biomarker panels for the detection of pancreatic cancer Clin. Cancer Res. 2011, 17, 805-16
10. Jiang, J. T.; Wu, C. P.; Deng, H. F.; Lu, M. Y.; Wu, J.; Zhang, H. Y.; Sun, W. H.; Ji, M. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer World J. Gastroenterol. 2004, 10, 1675-7
11. Kawa, S.; Tokoo, M.; Hasebe, O.; Hayashi, K.; Imai, H.; Oguchi, H.; Kiyosawa, K.; Furuta, S.; Homma, T. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer Br. J. Cancer 1994, 70, 481-6
12. Koopmann, J.; Rosenzweig, C. N.; Zhang, Z.; Canto, M. I.; Brown, D. A.; Hunter, M.; Yeo, C.; Chan, D. W.; Breit, S. N.; Goggins, M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9 Clin. Cancer Res. 2006, 12, 442-6
13. Fiedler, G. M.; Leichtle, A. B.; Kase, J.; Baumann, S.; Ceglarek, U.; Felix, K.; Conrad, T.; Witzigmann, H.; Weimann, A.; Schutte, C.; Hauss, J.; Buchler, M.; Thiery, J. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer Clin. Cancer Res. 2009, 15, 3812-9
14. Ching, C. K.; Rhodes, J. M.; Enzyme-linked, P. N. A. lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer Br. J. Cancer 1989, 59, 949-53
15. Yiannakou, J. Y.; Newland, P.; Calder, F.; Kingsnorth, A. N.; Rhodes, J. M. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer Lancet 1997, 349, 389-92
16. Wingren, C.; Sandstrom, A.; Segersvard, R.; Carlsson, A.; Andersson, R.; Lohr, M.; Borrebaeck, C. A. Identification of serum biomarker signatures associated with pancreatic cancer Cancer Res. 2012, 72, 2481-90
17. Nicholson, J. K.; Lindon, J. C.; Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data Xenobiotica 1999, 29, 1181-9
18. Fiehn, O. Metabolomics-the link between genotypes and phenotypes Plant Mol. Biol. 2002, 48, 155-71
19. Liesenfeld, D. B.; Habermann, N.; Owen, R. W.; Scalbert, A.; Ulrich, C. M. Review of mass spectrometry-based metabolomics in cancer research Cancer Epidemiol., Biomarkers Prev. 2013, 22, 2182-201
20. Chen, T.; Xie, G.; Wang, X.; Fan, J.; Qiu, Y.; Zheng, X.; Qi, X.; Cao, Y.; Su, M.; Xu, L. X.; Yen, Y.; Liu, P.; Jia, W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma Mol. Cell. Proteomics 2011, 10, M110.004945
21. Qiu, Y. P.; Cai, G. X.; Su, M. M.; Chen, T. L.; Zheng, X. J.; Xu, Y.; Ni, Y.; Zhao, A. H.; Xu, L. X.; Cai, S. J.; Jia, W. Serum Metabolite Profiling of Human Colorectal Cancer Using GC-TOFMS and UPLC-QTOFMS J. Proteome Res. 2009, 8, 4844-50
22. Wei, J.; Xie, G.; Zhou, Z.; Shi, P.; Qiu, Y.; Zheng, X.; Chen, T.; Su, M.; Zhao, A.; Jia, W. Salivary metabolite signatures of oral cancer and leukoplakia Int. J. Cancer 2011, 129, 2207-17
23. Cai, Z.; Zhao, J. S.; Li, J. J.; Peng, D. N.; Wang, X. Y.; Chen, T. L.; Qiu, Y. P.; Chen, P. P.; Li, W. J.; Xu, L. Y.; Li, E. M.; Tam, J. P.; Qi, R. Z.; Jia, W.; Xie, D. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism Mol. Cell. Proteomics 2010, 9, 2617-28
24. Nishiumi, S.; Shinohara, M.; Ikeda, A.; Yoshie, T.; Hatano, N.; Kakuyama, S.; Mizuno, S.; Sanuki, T.; Kutsumi, H.; Fukusaki, E.; Azuma, T.; Takenawa, T.; Yoshida, M. Serum metabolomics as a novel diagnostic approach for pancreatic cancer Metabolomics 2010, 6, 518-28
25. 1H nuclear magnetic resonance and principal components analysis Cancer Sci. 2007, 98, 1678-82
26. Bathe, O. F.; Shaykhutdinov, R.; Kopciuk, K.; Weljie, A. M.; McKay, A.; Sutherland, F. R.; Dixon, E.; Dunse, N.; Sotiropoulos, D.; Vogel, H. J. Feasibility of identifying pancreatic cancer based on serum metabolomics Cancer Epidemiol., Biomarkers Prev. 2011, 20, 140-7
27. Urayama, S.; Zou, W.; Brooks, K.; Tolstikov, V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer Rapid Commun. Mass Spectrom. 2010, 24, 613-20
28. Tesiram, Y. A.; Lerner, M.; Stewart, C.; Njoku, C.; Brackett, D. J. Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies Pancreas 2012, 41, 474-80
29. 1H NMR spectroscopy and principal component analysis Appl. Biochem. Biotechnol. 2011, 165, 148-54
30. Kobayashi, T.; Nishiumi, S.; Ikeda, A.; Yoshie, T.; Sakai, A.; Matsubara, A.; Izumi, Y.; Tsumura, H.; Tsuda, M.; Nishisaki, H.; Hayashi, N.; Kawano, S.; Fujiwara, Y.; Minami, H.; Takenawa, T.; Azuma, T.; Yoshida, M. A novel serum metabolomics-based diagnostic approach to pancreatic cancer Cancer Epidemiol Biomarkers Prev 2013, 22, 571-9
31. Fordahl, S.; Cooney, P.; Qiu, Y.; Xie, G.; Jia, W.; Erikson, K. M. Waterborne manganese exposure alters plasma, brain, and liver metabolites accompanied by changes in stereotypic behaviors Neurotoxicol. Teratol. 2012, 34, 27-36
32. Pike, N. Using false discovery rates for multiple comparisons in ecology and evolution Methods Ecol. Evol. 2011, 2, 278-82
33. Xia, J.; Wishart, D. S. MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data Nucleic Acids Res. 2010, 38, W71-7
34. Karnovsky, A.; Weymouth, T.; Hull, T.; Tarcea, V. G.; Scardoni, G.; Laudanna, C.; Sartor, M. A.; Stringer, K. A.; Jagadish, H. V.; Burant, C.; Athey, B.; Omenn, G. S. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data Bioinformatics 2012, 28, 373-80
35. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Res. 2003, 13, 2498-504
36. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-74
37. Le, A.; Rajeshkumar, N. V.; Maitra, A.; Dang, C. V. Conceptual framework for cutting the pancreatic cancer fuel supply Clin. Cancer Res. 2012, 18, 4285-90
38. Spratlin, J. L.; Serkova, N. J.; Eckhardt, S. G. Clinical applications of metabolomics in oncology: a review Clin. Cancer Res. 2009, 15, 431-40
39. Williams, R.; Lenz, E. M.; Wilson, A. J.; Granger, J.; Wilson, I. D.; Major, H.; Stumpf, C.; Plumb, R. A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats Mol. BioSyst. 2006, 2, 174-83
40. Pancreatic cancer; American Cancer Society: Atlanta, GA, 2014; http://www.cancer.org/acs/groups/cid/documents/webcontent/003131-pdf.pdf.
41. Schrader, H.; Menge, B. A.; Belyaev, O.; Uhl, W.; Schmidt, W. E.; Meier, J. J. Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma Pancreas 2009, 38, 416-21
42. Yamanouchi, T.; Akanuma, Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control Diabetes Res. Clin. Pract. 1994, 24, S261-8
43. Meier, R. F.; Beglinger, C. Nutrition in pancreatic diseases Best Pract. Res., Clin. Gastroenterol. 2006, 20, 507-29
44. Herner, A.; Sauliunaite, D.; Michalski, C. W.; Erkan, M.; De Oliveira, T.; Abiatari, I.; Kong, B.; Esposito, I.; Friess, H.; Kleeff, J. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling Int. J. Cancer 2011, 129, 2349-59
45. Cheng, L. L.; Anthony, D. C.; Comite, A. R.; Black, P. M.; Tzika, A. A.; Gonzalez, R. G. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy Neuro-Oncology 2000, 2, 87-95
46. Su, K. H.; Cuthbertson, C.; Christophi, C. Review of experimental animal models of acute pancreatitis HPB 2006, 8, 264-86
47. 1H-NMR metabolomics can distinguish pancreatitis patients from healthy controls J. Pancreas 2013, 14, 161-70